Výsledky vyhledávání - "Lieve Vandeplassche"

Effect of Prucalopride on the Pharmacokinetics of Oral Contraceptives in Healthy Women

Autor: V. Van de Velde, Mark Boterman, Lieve Vandeplassche, Jannie Ausma, Mieke Hoppenbrouwers

Publikováno v: Drugs in R&D

Background Prucalopride is a selective, high-affinity, 5-hydroxytryptamine 4 (5-HT4) receptor agonist, which is approved for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. Women of childb

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a451d11c96cf865374db747e6fcb56c0
https://doi.org/10.1007/s40268-013-0008-6

Zobrazit plný text záznamu

Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study

Autor: Rene Kerstens, Patricia Robinson, John Camm, Dennis O. Chanter, Jannie Ausma, Boaz Mendzelevski, Lieve Vandeplassche

Publikováno v: British Journal of Clinical Pharmacology. 73:203-209

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Drugs interacting with the hERG potassium channel are associated with a prolongation of the QT interval, which can lead to life-threatening arrhythmias such as torsades de pointes. • Early prokinetic age

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::690961801c4d3255cda7b36ed15edc6e
https://doi.org/10.1111/j.1365-2125.2011.04088.x

Zobrazit plný text záznamu

Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction - a double-blind, placebo-controlled, cross-over, multiple n = 1 study

Autor: Rene Kerstens, Michael A. Kamm, Anton Emmanuel, A J Roy, Lieve Vandeplassche

Publikováno v: Alimentary Pharmacology & Therapeutics. 35:48-55

Aliment Pharmacol Ther 2012; 35: 48–55 Summary Background Chronic intestinal pseudo-obstruction is a disabling condition for which there are no established drug therapies. The condition is caused by a diverse range of intestinal myopathies and neur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5fa739cdaebb5003344b974382d92b0d
https://doi.org/10.1111/j.1365-2036.2011.04907.x

Zobrazit plný text záznamu

Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies

Autor: M J Van Outryve, Michael Camilleri, Greet Beyens, P. Robinson, Rene Kerstens, Lieve Vandeplassche

Publikováno v: Alimentary Pharmacology & Therapeutics. 32:1113-1123

Aliment Pharmacol Ther 2010; 32: 1113–1123 Summary Background Prucalopride is approved in Europe for symptomatic treatment of chronic constipation in women with inadequate relief from laxatives. Aim To evaluate efficacy of prucalopride during long-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::524bb0ed46233b9a486edccaed98bbd6
https://doi.org/10.1111/j.1365-2036.2010.04455.x

Zobrazit plný text záznamu

Plný text ve formátu HTML

Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives

Autor: M J Van Outryve, Jan Tack, Rene Kerstens, Georges Beyens, Lieve Vandeplassche

Publikováno v: Gut : the journal of the British Society for Gastroenterology

Objective: To determine the efficacy, impact on quality of life (QOL) and safety of prucalopride, a selective, high-affinity 5-HT(4) receptor agonist, in patients with chronic constipation. Methods: In this multicentre, randomised, placebo controlled

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff2c5dc58376f25569fc8067564a2983
https://doi.org/10.1136/gut.2008.162404

Zobrazit plný text záznamu

Association between health-related quality of life and symptoms in patients with chronic constipation: an integrated analysis of three phase 3 trials of prucalopride

Autor: Alain Joseph, Lieve Vandeplassche, Jan Tack, Dominique Dubois, Michael Camilleri, Rene Kerstens

Publikováno v: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. 27(3)

Background Prucalopride is a high-affinity 5-HT4 receptor agonist for the treatment of chronic constipation. The aims of this study were to investigate the relationship between health-related quality of life (HRQoL) and symptoms of constipation, and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33ba5b2999eae08a47413984729b52ec
https://pubmed.ncbi.nlm.nih.gov/25581251

Zobrazit plný text záznamu

Prucalopride improves bowel function and colonic transit time in patients with chronic constipation: an integrated analysis

Autor: Marina Cools, Anton Emmanuel, Lieve Vandeplassche, Rene Kerstens

Publikováno v: The American Journal of Gastroenterology

OBJECTIVES: Constipation is often characterized by slow colonic transit, but the relationship between colonic transit time (CTT) and symptoms is unclear. The aims of this study were to investigate the effect of prucalopride, a 5-hydroxytryptamine rec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::047e6cd9fc816baff85a607af7eeb035
https://pubmed.ncbi.nlm.nih.gov/24732867

Zobrazit plný text záznamu

Oral prucalopride in children with functional constipation

Autor: Mark A. Gilger, Harland S. Winter, Gregory L. Kearns, Jannie Ausma, Carlo Di Lorenzo, Mieke Hoppenbrouwers, Marc A. Benninga, Paul E. Hyman, Lieve Vandeplassche

Publikováno v: Journal of pediatric gastroenterology and nutrition, 57(2), 197-203. Lippincott Williams and Wilkins

Background and objectives Prucalopride is a selective, high-affinity 5-HT4 receptor agonist with gastrointestinal prokinetic activities. The aim of this study was to evaluate the pharmacokinetics, efficacy, safety, and tolerability of prucalopride or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6803fc16a87f7b63426a0a769aa546e7
https://pubmed.ncbi.nlm.nih.gov/23535761

Zobrazit plný text záznamu

Factors affecting satisfaction with treatment in European women with chronic constipation

Autor: Stefan Müller-Lissner, Jan Tack, Viola Andresen, Jean Marc Sabate, Yue Feng, Magnus Simren, Albert J. Bredenoord, Enrique Rey, Anton Emmanuel, Daniel Urbain, Rosario Cuomo, Eamonn Martin Quigley, Lieve Vandeplassche, Renate Specht Gryp, Yan Yiannakou, Dory Solomon

Publikováno v: United European gastroenterology journal, 1(5), 375-384. SAGE Publications Inc.

Background: Data on factors affecting treatment satisfaction in European women with chronic constipation are limited. Objective: To assess factors associated with treatment satisfaction among European women with chronic constipation. Methods: A 2011-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebd8abb00f3cbb2c947c7e85f042ba63
https://hdl.handle.net/20.500.14017/e32b6b8c-89c9-422b-a47f-825460895a40

Zobrazit plný text záznamu

Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis

Autor: Rene Kerstens, Michael Camilleri, Jan Tack, Lieve Vandeplassche, Eamonn Martin Quigley

Publikováno v: United European gastroenterology journal. 1(1)

Prucalopride is a selective, high-affinity, 5-hydroxytryptamine (serotonin) type 4 (5-HT4) receptor agonist with gastrointestinal prokinetic activities. This integrated analysis of data from three double-blind phase III trials (ClinicalTrials.gov: NC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86665e34340bf75926797e1eb91f3aa9
https://pubmed.ncbi.nlm.nih.gov/24917940

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání